leisure time -WSS

leisure time

author：knowledge 2025-08-12 09:13:38 - browse：2195

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： STAT series 'Denied by AI' wins major journalism prizes

entertainment

WSS

Texas board proposes rules on abortion law emergency exemption

Chinese researcher claims birth of first gene

As H5N1 spreads in cows, experts warn against drinking raw milk

Biotech investment managers search for lucrative opportunities

Free medical tuition alone isn't enough to close gaps in primary care

The United States must get value

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Apple is now the first public company to be valued at $3 trillion

Cancer, immunology, HIV research ensnared in fetal tissue politics

Novavax promises a turnaround & Lilly roils the obesity market

'Patient friction coefficient' can gauge a clinical trial's patient burden

Bright Health sells Medicare Advantage business to Molina

WuXi Biologics beefs up its lobbying operation

Heart attack and stroke risk calculators need revising

U.K. officials, researchers try to ease path for bespoke genetic treatments

Dobbs anniversary: the lost opportunity of abortion as health care

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

focus

Medical devices makers are asking for forgiveness, not permission

HHS suspends federal funding for EcoHealth Alliance

STAT series 'Denied by AI' wins major journalism prizes

Adam's Take: Intra

Diabetes management: Digital health tools fall short, study says

As H5N1 spreads in cows, experts warn against drinking raw milk

explore

entertainment

leisure time

leisure time